278 related articles for article (PubMed ID: 30669372)
21. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
Ehm P; Grottke A; Bettin B; Jücker M
Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
23. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
24. The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.
Adam E; Kim HN; Gang EJ; Schnair C; Lee S; Lee S; Khazal S; Kosoyan O; Konopleva M; Parekh C; Bhojwani D; Wayne AS; Abdel-Azim H; Heisterkamp N; Kim YM
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28891959
[TBL] [Abstract][Full Text] [Related]
25. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
Sathe A; Nawroth R
Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
[TBL] [Abstract][Full Text] [Related]
27. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.
Shalapour S; Hof J; Kirschner-Schwabe R; Bastian L; Eckert C; Prada J; Henze G; von Stackelberg A; Seeger K
Haematologica; 2011 Nov; 96(11):1627-35. PubMed ID: 21828124
[TBL] [Abstract][Full Text] [Related]
28. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
29. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells.
Goswami A; Shah BA; Kumar A; Rizvi MA; Kumar S; Bhushan S; Malik FA; Batra N; Joshi A; Singh J
Chem Biol Interact; 2014 Oct; 222():60-7. PubMed ID: 25196075
[TBL] [Abstract][Full Text] [Related]
31. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia.
Wang X; Zhang X; Li BS; Zhai X; Yang Z; Ding LX; Wang H; Liang C; Zhu W; Ding J; Meng LH
Oncotarget; 2014 Nov; 5(21):10732-44. PubMed ID: 25313141
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
34. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
35. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
36. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
37. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
[TBL] [Abstract][Full Text] [Related]
38. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
39. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Gomes AM; Soares MV; Ribeiro P; Caldas J; Póvoa V; Martins LR; Melão A; Serra-Caetano A; de Sousa AB; Lacerda JF; Barata JT
Haematologica; 2014 Jun; 99(6):1062-8. PubMed ID: 24561792
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
